Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: Myeloablative or reduced intensity?

Ulrike Bacher, Evgeny Klyuchnikov, Jennifer Le-Rademacher, Jeanette Carreras, Philippe Armand, Michael R. Bishop, Christopher N. Bredeson, Mitchell S. Cairo, Timothy S. Fenske, Cesar O. Freytes, Robert Peter Gale, John Gibson, Luis M. Isola, David J. Inwards, Ginna G. Laport, Hillard M. Lazarus, Richard T. Maziarz, Peter H. Wiernik, Harry C. Schouten, Shimon SlavinSonali M. Smith, Julie Marie Vose, Edmund K. Waller, Parameswaran N. Hari

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

The best conditioning regimen before allogeneic transplantation for high-risk diffuse large B-cell lymphoma (DLBCL) remains to be clarified. We analyzed data from 396 recipients of allotransplants for DLBCL receiving myeloablative (MAC; n = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens. Acute and chronic GVHD rates were similar across the groups. Five-year nonrelapse mortality (NRM) was higher in MAC than RIC and NMAC (56% vs 47% vs 36%; P = .007). Five-year relapse/progression was lower in MAC than in RIC/NMAC (26% vs 38% vs 40%; P = .031). Five-year progression-free survival (15%-25%) and overall survival (18%-26%) did not differ significantly between the cohorts. In multivariate analysis, NMAC and more recent transplant year were associated with lower NRM, whereas a lower Karnofsky performance score (< 90), prior relapse resistant to therapy, and use of unrelated donors were associated with higher NRM. NMAC transplants, no prior use of rituximab, and prior relapse resistant to therapy were associated with a greater risk of relapse/progression. In conclusion, allotransplantation with RIC or NMAC induces long-term progressionfree survival in selected DLBCL patients with a lower risk of NRM but with higher risk of lymphoma progression or relapse.

Original languageEnglish (US)
Pages (from-to)4256-4262
Number of pages7
JournalBlood
Volume120
Issue number20
DOIs
StatePublished - Nov 15 2012

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Cells
Recurrence
Transplants
Mortality
Unrelated Donors
Survival
Homologous Transplantation
Disease-Free Survival
Lymphoma
Multivariate Analysis
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Bacher, U., Klyuchnikov, E., Le-Rademacher, J., Carreras, J., Armand, P., Bishop, M. R., ... Hari, P. N. (2012). Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: Myeloablative or reduced intensity? Blood, 120(20), 4256-4262. https://doi.org/10.1182/blood-2012-06-436725

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma : Myeloablative or reduced intensity? / Bacher, Ulrike; Klyuchnikov, Evgeny; Le-Rademacher, Jennifer; Carreras, Jeanette; Armand, Philippe; Bishop, Michael R.; Bredeson, Christopher N.; Cairo, Mitchell S.; Fenske, Timothy S.; Freytes, Cesar O.; Gale, Robert Peter; Gibson, John; Isola, Luis M.; Inwards, David J.; Laport, Ginna G.; Lazarus, Hillard M.; Maziarz, Richard T.; Wiernik, Peter H.; Schouten, Harry C.; Slavin, Shimon; Smith, Sonali M.; Vose, Julie Marie; Waller, Edmund K.; Hari, Parameswaran N.

In: Blood, Vol. 120, No. 20, 15.11.2012, p. 4256-4262.

Research output: Contribution to journalArticle

Bacher, U, Klyuchnikov, E, Le-Rademacher, J, Carreras, J, Armand, P, Bishop, MR, Bredeson, CN, Cairo, MS, Fenske, TS, Freytes, CO, Gale, RP, Gibson, J, Isola, LM, Inwards, DJ, Laport, GG, Lazarus, HM, Maziarz, RT, Wiernik, PH, Schouten, HC, Slavin, S, Smith, SM, Vose, JM, Waller, EK & Hari, PN 2012, 'Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: Myeloablative or reduced intensity?', Blood, vol. 120, no. 20, pp. 4256-4262. https://doi.org/10.1182/blood-2012-06-436725
Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: Myeloablative or reduced intensity? Blood. 2012 Nov 15;120(20):4256-4262. https://doi.org/10.1182/blood-2012-06-436725
Bacher, Ulrike ; Klyuchnikov, Evgeny ; Le-Rademacher, Jennifer ; Carreras, Jeanette ; Armand, Philippe ; Bishop, Michael R. ; Bredeson, Christopher N. ; Cairo, Mitchell S. ; Fenske, Timothy S. ; Freytes, Cesar O. ; Gale, Robert Peter ; Gibson, John ; Isola, Luis M. ; Inwards, David J. ; Laport, Ginna G. ; Lazarus, Hillard M. ; Maziarz, Richard T. ; Wiernik, Peter H. ; Schouten, Harry C. ; Slavin, Shimon ; Smith, Sonali M. ; Vose, Julie Marie ; Waller, Edmund K. ; Hari, Parameswaran N. / Conditioning regimens for allotransplants for diffuse large B-cell lymphoma : Myeloablative or reduced intensity?. In: Blood. 2012 ; Vol. 120, No. 20. pp. 4256-4262.
@article{acb84e4260da4d79be90e97da1bd1d31,
title = "Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: Myeloablative or reduced intensity?",
abstract = "The best conditioning regimen before allogeneic transplantation for high-risk diffuse large B-cell lymphoma (DLBCL) remains to be clarified. We analyzed data from 396 recipients of allotransplants for DLBCL receiving myeloablative (MAC; n = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens. Acute and chronic GVHD rates were similar across the groups. Five-year nonrelapse mortality (NRM) was higher in MAC than RIC and NMAC (56{\%} vs 47{\%} vs 36{\%}; P = .007). Five-year relapse/progression was lower in MAC than in RIC/NMAC (26{\%} vs 38{\%} vs 40{\%}; P = .031). Five-year progression-free survival (15{\%}-25{\%}) and overall survival (18{\%}-26{\%}) did not differ significantly between the cohorts. In multivariate analysis, NMAC and more recent transplant year were associated with lower NRM, whereas a lower Karnofsky performance score (< 90), prior relapse resistant to therapy, and use of unrelated donors were associated with higher NRM. NMAC transplants, no prior use of rituximab, and prior relapse resistant to therapy were associated with a greater risk of relapse/progression. In conclusion, allotransplantation with RIC or NMAC induces long-term progressionfree survival in selected DLBCL patients with a lower risk of NRM but with higher risk of lymphoma progression or relapse.",
author = "Ulrike Bacher and Evgeny Klyuchnikov and Jennifer Le-Rademacher and Jeanette Carreras and Philippe Armand and Bishop, {Michael R.} and Bredeson, {Christopher N.} and Cairo, {Mitchell S.} and Fenske, {Timothy S.} and Freytes, {Cesar O.} and Gale, {Robert Peter} and John Gibson and Isola, {Luis M.} and Inwards, {David J.} and Laport, {Ginna G.} and Lazarus, {Hillard M.} and Maziarz, {Richard T.} and Wiernik, {Peter H.} and Schouten, {Harry C.} and Shimon Slavin and Smith, {Sonali M.} and Vose, {Julie Marie} and Waller, {Edmund K.} and Hari, {Parameswaran N.}",
year = "2012",
month = "11",
day = "15",
doi = "10.1182/blood-2012-06-436725",
language = "English (US)",
volume = "120",
pages = "4256--4262",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "20",

}

TY - JOUR

T1 - Conditioning regimens for allotransplants for diffuse large B-cell lymphoma

T2 - Myeloablative or reduced intensity?

AU - Bacher, Ulrike

AU - Klyuchnikov, Evgeny

AU - Le-Rademacher, Jennifer

AU - Carreras, Jeanette

AU - Armand, Philippe

AU - Bishop, Michael R.

AU - Bredeson, Christopher N.

AU - Cairo, Mitchell S.

AU - Fenske, Timothy S.

AU - Freytes, Cesar O.

AU - Gale, Robert Peter

AU - Gibson, John

AU - Isola, Luis M.

AU - Inwards, David J.

AU - Laport, Ginna G.

AU - Lazarus, Hillard M.

AU - Maziarz, Richard T.

AU - Wiernik, Peter H.

AU - Schouten, Harry C.

AU - Slavin, Shimon

AU - Smith, Sonali M.

AU - Vose, Julie Marie

AU - Waller, Edmund K.

AU - Hari, Parameswaran N.

PY - 2012/11/15

Y1 - 2012/11/15

N2 - The best conditioning regimen before allogeneic transplantation for high-risk diffuse large B-cell lymphoma (DLBCL) remains to be clarified. We analyzed data from 396 recipients of allotransplants for DLBCL receiving myeloablative (MAC; n = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens. Acute and chronic GVHD rates were similar across the groups. Five-year nonrelapse mortality (NRM) was higher in MAC than RIC and NMAC (56% vs 47% vs 36%; P = .007). Five-year relapse/progression was lower in MAC than in RIC/NMAC (26% vs 38% vs 40%; P = .031). Five-year progression-free survival (15%-25%) and overall survival (18%-26%) did not differ significantly between the cohorts. In multivariate analysis, NMAC and more recent transplant year were associated with lower NRM, whereas a lower Karnofsky performance score (< 90), prior relapse resistant to therapy, and use of unrelated donors were associated with higher NRM. NMAC transplants, no prior use of rituximab, and prior relapse resistant to therapy were associated with a greater risk of relapse/progression. In conclusion, allotransplantation with RIC or NMAC induces long-term progressionfree survival in selected DLBCL patients with a lower risk of NRM but with higher risk of lymphoma progression or relapse.

AB - The best conditioning regimen before allogeneic transplantation for high-risk diffuse large B-cell lymphoma (DLBCL) remains to be clarified. We analyzed data from 396 recipients of allotransplants for DLBCL receiving myeloablative (MAC; n = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens. Acute and chronic GVHD rates were similar across the groups. Five-year nonrelapse mortality (NRM) was higher in MAC than RIC and NMAC (56% vs 47% vs 36%; P = .007). Five-year relapse/progression was lower in MAC than in RIC/NMAC (26% vs 38% vs 40%; P = .031). Five-year progression-free survival (15%-25%) and overall survival (18%-26%) did not differ significantly between the cohorts. In multivariate analysis, NMAC and more recent transplant year were associated with lower NRM, whereas a lower Karnofsky performance score (< 90), prior relapse resistant to therapy, and use of unrelated donors were associated with higher NRM. NMAC transplants, no prior use of rituximab, and prior relapse resistant to therapy were associated with a greater risk of relapse/progression. In conclusion, allotransplantation with RIC or NMAC induces long-term progressionfree survival in selected DLBCL patients with a lower risk of NRM but with higher risk of lymphoma progression or relapse.

UR - http://www.scopus.com/inward/record.url?scp=84869850112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869850112&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-06-436725

DO - 10.1182/blood-2012-06-436725

M3 - Article

C2 - 23007405

AN - SCOPUS:84869850112

VL - 120

SP - 4256

EP - 4262

JO - Blood

JF - Blood

SN - 0006-4971

IS - 20

ER -